Pharmacogenomics 💊🧬

  Tamoxifene, a drug widely used in the treatment of estrogen receptor-positive breast cancer, has shown varying responses in different individuals. This discrepancy in treatment outcomes has led researchers to explore the field of pharmacogenomics to understand how genetic factors influence the metabolism and effectiveness of tamoxifen. By unraveling the genetic underpinnings of drug response, personalized medicine approaches can be developed to tailor treatment plans for better outcomes. One of the key focuses in tamoxifene pharmacogenomics is the enzyme CYP2D6, which plays a crucial role in converting tamoxifene into its active form, endoxifen. Genetic variations in the CYP2D6 gene can result in individuals being classified as normal, poor, or intermediate metabolizers based on their ability to activate tamoxifene. Poor metabolizers, for instance, may experience reduced effectiveness of tamoxifene therapy due to lower levels of active metabolites. Understanding a patient's CYP2D...